Related Experiment Videos

Resolution of acromegalic cardiomyopathy in mild acromegalic physical abnormality after short-term octreotide therapy

Myung-Woo Hwang1, Akira Shimatsu, Yoshio Sasaki

  • 1Department of Cardiovascular Medicine, Ijinkai-Takeda General Hospital, 28-1 Ishidamori, Minami-machi, Fushimi-ku, Kyoto, 601-1495, Japan.

Heart and Vessels
|May 30, 2007
PubMed

Insights

Early diagnosis and treatment of acromegaly can reverse heart failure. Somatostatin analog therapy and surgery effectively treated acromegalic cardiomyopathy in a patient with congestive heart failure.

Area of Science:

  • Cardiology
  • Endocrinology
  • Oncology

Background:

  • Acromegalic cardiomyopathy is a serious complication of excess growth hormone.
  • It can lead to congestive heart failure and impaired cardiac function.

Observation:

  • A 42-year-old man with mild acromegalic features developed congestive heart failure.
  • Echocardiography revealed left ventricular dilatation and reduced systolic function.
  • Elevated growth hormone and insulin-like growth factor-1 confirmed acromegaly, linked to a pituitary microadenoma.

Findings:

  • Conventional treatment was ineffective.
  • Short-term octreotide (somatostatin analog) rapidly improved cardiac function.
  • Further improvement occurred after octreotide discontinuation, with minimal residual diastolic dysfunction.
  • Successful trans-sphenoidal surgery allowed cessation of all medical treatment.

Implications:

  • Early diagnosis and treatment are crucial for reversing acromegalic cardiomyopathy.
  • Somatostatin analogs and surgical intervention are effective therapeutic options.
  • Complete recovery from acromegalic cardiomyopathy is possible with timely and appropriate management.

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...